BridgeMD
Dose monitoring of commonly used cytostatic drugs for breast cancer
EU CTIS ID: 2024-514818-12-00
What this study is testing
To measure cytotoxic drugs, i.e., epirubicin, cyclophosphamide, docetaxel, paclitaxel and doxorubicin, used in routine treatment of breast cancer, and to search for correlations between exposure (AUC) and side effects. The intention is to offer future patients individualized dose adjustments to avoid both over- and under-treatment.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Female patients aged ≥ 18 years.
- Treated with any, or a combination, of the drugs cyclophosphamide, epirubicin, doxorubicin, docetaxel and paclitaxel.
- Written informed consent.
You likely can't join if
- Patients fulfilling any of the contraindications mentioned for the studied drugs.
- Patients treated with a combinatorial regime of docetaxel, carboplatin and trastuzumab.
- Patients receiving palliative chemotherapy.
- Patients included in other clinical studies receiving not approved investigational medicinal drug.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.